NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Down 0.2 %

NASDAQ:NURO opened at $4.00 on Monday. The company has a market capitalization of $8.12 million, a P/E ratio of -0.72 and a beta of 2.29. The firm has a 50-day moving average price of $4.04 and a two-hundred day moving average price of $3.89. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The business had revenue of $0.77 million for the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.